Recent Pfizer Press Releases

  • 4/21/08 10:52 am EDT
    NEW YORK--(BUSINESS WIRE)-- Pfizer Inc announced today that Lipitor® (atorvastatin calcium) 80 mg reduced the risk of heart attack and stroke by 32 percent in patients who have heart disease and chronic kidney disease compared with patients taking the 10 mg dose of Lipitor. This analysis, designed and completed following the closure of the five-year Treating to New Targets (TNT) study, was published in the “Journal of the Americanmore...
  • 4/21/08 10:30 am EDT

    For the Treatment of Two Difficult-to-Treat Advanced Cancers

    TOKYO--(BUSINESS WIRE)--Pfizer Japan Inc announced that on April 16, the company received an approval for the manufacturing and marketing authorization of the anti-tumor drug/kinase inhibitor “SUTENT® Capsule 12.5 mg” (sunitinib malate) indicated for Gastrointestinal Stromal Tumor (GIST) after failure of imatinib treatment due to resistance and for Renal Cell Carcinoma (RCC) not indicated for curative resection and Metastatic Renalmore...
  • 4/18/08 10:36 am EDT
    BRUSSELS, Belgium--(BUSINESS WIRE)--A new development centre for veterinary vaccines which will accelerate the development of new animal health products has been opened by Pfizer as part of its annual $300 million (US dollar) commitment to research and development. The new centre is located on the Louvain-la-Neuve scientific plant near Brussels. "This is an historic occasion for Pfizer Animal Health,” said Juan Ramonmore...
  • 4/17/08 4:24 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Canadian Federal Court has upheld a Pfizer patent covering amlodipine besylate, the active ingredient in Norvasc. The court issued an order prohibiting regulatory approval of Pharmascience’s proposed product in Canada until Pfizer’s amlodipine besylate patent - Canadian Patent No. 1,321,393 - expires in August 2010. Pharmascience may appeal the decision to the Federal Court of Appealmore...
  • 4/17/08 7:00 am EDT
    • Pfizer Reaffirms Full-Year 2008 Financial Guidance Previously Provided; On-track to Achieve Cost-Reduction Targets
    • First-Quarter 2008 Revenues of $11.8 Billion Compared with $12.5 Billion in the Year-Ago Quarter
    • First-Quarter 2008 Reported Diluted EPS of $0.41 Compared with $0.48 in the Year-Ago Quarter
    • First-Quarter 2008 Adjusted Diluted EPS(1) of $0.61 Compared with $0.68 in the Year-Ago Quarter
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE):         ($ in millions, except per share amounts)         First Quarter   2008  more...
  • 4/16/08 7:33 pm EDT

    Study Further Confirms Safety Profile of Lipitor 80 mg In Elderly Patients

    NEW YORK--(BUSINESS WIRE)--In a study in patients with mild-to-moderate Alzheimer’s disease (AD), the addition of Lipitor (atorvastatin calcium tablets) 80 mg to Aricept® (donepezil HCl) 10 mg showed no significant differences in cognition or global function (key measures of Alzheimer’s progression) compared to placebo plus Aricept 10 mg. Furthermore, no statistically significant differences were seen on various cognitive, behavioralmore...
  • 4/16/08 4:37 pm EDT
    NEW YORK & NEEDHAM, Mass.--(BUSINESS WIRE)--Pfizer, Inc (NYSE: PFE) and AVANT Immunotherapeutics (Nasdaq: AVAN), acting through its wholly-owned subsidiary Celldex Therapeutics, Inc. today announced that they have entered into an agreement under which Pfizer will be granted an exclusive worldwide license to a therapeutic cancer vaccine candidate, CDX-110, in Phase 2 development for the treatment of glioblastoma multiforme (GBM). This agreement also givesmore...
  • 4/16/08 8:00 am EDT

    Patient Reports of Improvement Linked to Reduction in Pain and Enhanced Sleep

    CHICAGO--(BUSINESS WIRE)--Pfizer’s Lyrica reduced pain of fibromyalgia in patients regardless of whether they experienced symptoms of anxiety or depression at the beginning of the study, according to a pooled analysis presented today at the American Academy of Neurology annual meeting. The analysis, which looked at data pooled from previous clinical trials, also showed that patients’ self-reported improvements were more closely associatedmore...
  • 4/15/08 8:15 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced that the subsequent offering period of the tender offer by its wholly-owned subsidiary, Explorer Acquisition Corp., to purchase all of the outstanding shares of common stock of Encysive Pharmaceuticals Inc. (NASDAQ: ENCY) at a purchase price of $2.35 per share, net to the seller in cash, without interest thereon and less any required withholding taxes, expired as of 5:00 p.m., New Yorkmore...
  • 4/9/08 8:30 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that it updated the US product labeling for EXUBERA® (insulin human [rDNA original]) Inhalation Powder to include a warning with safety information about lung cancer cases observed in patients who used Exubera. This update is based on an ongoing review of the data from the Exubera clinical trial program and post-marketing experience by Pfizer and the Food and Drug Administration (FDA).more...